Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.45)
# 371
Out of 4,413 analysts
79
Total ratings
43.33%
Success rate
36.42%
Average return
Main Sectors:
Top Industries:
31 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGTX Cognition Therapeutics | Reiterates: Buy | $5 | $1.91 | +161.78% | 1 | Mar 28, 2024 | |
| ALT Altimmune | Reiterates: Buy | $20 | $6.55 | +205.34% | 6 | Mar 28, 2024 | |
| MDGL Madrigal Pharmaceuticals | Upgrades: Neutral | $155 → $270 | $204.02 | +32.34% | 6 | Mar 15, 2024 | |
| TGTX TG Therapeutics | Maintains: Buy | $24 → $29 | $13.66 | +112.30% | 10 | Feb 5, 2024 | |
| VXRT Vaxart | Upgrades: Buy | $2 | $0.71 | +179.84% | 4 | Jan 31, 2024 | |
| CKPT Checkpoint Therapeutics | Maintains: Buy | $8 → $4 | $1.39 | +187.77% | 2 | Dec 20, 2023 | |
| CYTK Cytokinetics | Initiates: Buy | $66 | $61.32 | +7.63% | 1 | Nov 7, 2023 | |
| SCLX Scilex Holding Company | Initiates: Buy | $4 | $0.85 | +368.82% | 1 | Oct 13, 2023 | |
| DNLI Denali Therapeutics | Initiates: Buy | $38 | $15.44 | +146.11% | 1 | Sep 6, 2023 | |
| NVAX Novavax | Upgrades: Buy | $15 | $4.33 | +246.42% | 10 | Aug 9, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Buy | $55 | $22.62 | +143.15% | 5 | Jul 20, 2023 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $6 | $2.93 | +104.78% | 1 | Apr 12, 2023 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $7 → $3 | $1.12 | +167.86% | 3 | Apr 10, 2023 | |
| AGEN Agenus | Reiterates: Buy | $160 | $12.12 | +1,220.13% | 1 | Mar 29, 2023 | |
| GRTS Gritstone bio | Initiates: Buy | $8 | $0.80 | +900.00% | 1 | Mar 28, 2023 | |
| GANX Gain Therapeutics | Downgrades: Neutral | $11 → $5 | $2.93 | +70.65% | 3 | Aug 19, 2022 | |
| SAVA Cassava Sciences | Maintains: Buy | $58 → $44 | $22.15 | +98.65% | 3 | Aug 11, 2022 | |
| FBIO Fortress Biotech | Maintains: Buy | $120 → $90 | $1.67 | +5,289.22% | 3 | Jul 14, 2022 | |
| LCTX Lineage Cell Therapeutics | Initiates: Buy | $4 | $1.09 | +266.97% | 1 | Jun 14, 2022 | |
| INMB INmune Bio | Downgrades: Neutral | $14 → $7 | $11.84 | -40.88% | 2 | May 24, 2022 | |
| TFFP TFF Pharmaceuticals | Maintains: Buy | $600 → $450 | $2.73 | +16,383.52% | 1 | Mar 29, 2022 | |
| SEEL Seelos Therapeutics | Maintains: Buy | $180 → $120 | $0.28 | +42,910.75% | 2 | Mar 14, 2022 | |
| MBIO Mustang Bio | Maintains: Buy | $195 → $90 | $0.25 | +36,190.32% | 1 | Jan 24, 2022 | |
| BIVI BioVie | Maintains: Buy | n/a | $0.49 | - | 1 | Nov 30, 2021 | |
| ELOX Eloxx Pharmaceuticals | Initiates: Buy | n/a | $0.91 | - | 1 | May 27, 2021 | |
| ARCT Arcturus Therapeutics Holdings | Downgrades: Neutral | n/a | $25.57 | - | 2 | Jan 15, 2021 | |
| ACST Acasti Pharma | Upgrades: Buy | n/a | $2.78 | - | 1 | Jul 6, 2020 | |
| GLMD Galmed Pharmaceuticals | Downgrades: Neutral | n/a | $0.35 | - | 2 | May 22, 2020 | |
| GALT Galectin Therapeutics | Maintains: Buy | n/a | $3.51 | - | 1 | Apr 3, 2020 | |
| MNOV MediciNova | Maintains: Buy | n/a | $1.29 | - | 1 | Mar 13, 2020 | |
| GNFT Genfit | Maintains: Buy | n/a | $3.50 | - | 1 | Mar 13, 2020 |
Cognition Therapeutics
Mar 28, 2024
Reiterates: Buy
Price Target: $5
Current: $1.91
Upside: +161.78%
Altimmune
Mar 28, 2024
Reiterates: Buy
Price Target: $20
Current: $6.55
Upside: +205.34%
Madrigal Pharmaceuticals
Mar 15, 2024
Upgrades: Neutral
Price Target: $155 → $270
Current: $204.02
Upside: +32.34%
TG Therapeutics
Feb 5, 2024
Maintains: Buy
Price Target: $24 → $29
Current: $13.66
Upside: +112.30%
Vaxart
Jan 31, 2024
Upgrades: Buy
Price Target: $2
Current: $0.71
Upside: +179.84%
Checkpoint Therapeutics
Dec 20, 2023
Maintains: Buy
Price Target: $8 → $4
Current: $1.39
Upside: +187.77%
Cytokinetics
Nov 7, 2023
Initiates: Buy
Price Target: $66
Current: $61.32
Upside: +7.63%
Scilex Holding Company
Oct 13, 2023
Initiates: Buy
Price Target: $4
Current: $0.85
Upside: +368.82%
Denali Therapeutics
Sep 6, 2023
Initiates: Buy
Price Target: $38
Current: $15.44
Upside: +146.11%
Novavax
Aug 9, 2023
Upgrades: Buy
Price Target: $15
Current: $4.33
Upside: +246.42%
Arrowhead Pharmaceuticals
Jul 20, 2023
Reiterates: Buy
Price Target: $55
Current: $22.62
Upside: +143.15%
Trevi Therapeutics
Apr 12, 2023
Initiates: Buy
Price Target: $6
Current: $2.93
Upside: +104.78%
X4 Pharmaceuticals
Apr 10, 2023
Maintains: Buy
Price Target: $7 → $3
Current: $1.12
Upside: +167.86%
Agenus
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $12.12
Upside: +1,220.13%
Gritstone bio
Mar 28, 2023
Initiates: Buy
Price Target: $8
Current: $0.80
Upside: +900.00%
Gain Therapeutics
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $2.93
Upside: +70.65%
Cassava Sciences
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $22.15
Upside: +98.65%
Fortress Biotech
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $1.67
Upside: +5,289.22%
Lineage Cell Therapeutics
Jun 14, 2022
Initiates: Buy
Price Target: $4
Current: $1.09
Upside: +266.97%
INmune Bio
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $11.84
Upside: -40.88%
TFF Pharmaceuticals
Mar 29, 2022
Maintains: Buy
Price Target: $600 → $450
Current: $2.73
Upside: +16,383.52%
Seelos Therapeutics
Mar 14, 2022
Maintains: Buy
Price Target: $180 → $120
Current: $0.28
Upside: +42,910.75%
Mustang Bio
Jan 24, 2022
Maintains: Buy
Price Target: $195 → $90
Current: $0.25
Upside: +36,190.32%
BioVie
Nov 30, 2021
Maintains: Buy
Price Target: n/a
Current: $0.49
Upside: -
Eloxx Pharmaceuticals
May 27, 2021
Initiates: Buy
Price Target: n/a
Current: $0.91
Upside: -
Arcturus Therapeutics Holdings
Jan 15, 2021
Downgrades: Neutral
Price Target: n/a
Current: $25.57
Upside: -
Acasti Pharma
Jul 6, 2020
Upgrades: Buy
Price Target: n/a
Current: $2.78
Upside: -
Galmed Pharmaceuticals
May 22, 2020
Downgrades: Neutral
Price Target: n/a
Current: $0.35
Upside: -
Galectin Therapeutics
Apr 3, 2020
Maintains: Buy
Price Target: n/a
Current: $3.51
Upside: -
MediciNova
Mar 13, 2020
Maintains: Buy
Price Target: n/a
Current: $1.29
Upside: -
Genfit
Mar 13, 2020
Maintains: Buy
Price Target: n/a
Current: $3.50
Upside: -